Zydus receives final approval for Aspirin and Extended-Release Dipyridamole Capsules

30 Aug 2017 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Aspirin and Extended-Release Dipyridamole Capsules in the strength of 25 mg/200 mg. The drug is an antiplatelet agent which works in the prevention of excessive blood clotting and is used to reduce the risk of stroke in patients who have had or are at risk of stroke.

The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The sales of Aspirin and Extended-Release Dipyridamole Capsules are estimated at $198.7 million, as per IMS Health. The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.


Zydus Lifesciences Share Price

913.90 -7.35 (-0.80%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×